ライフサイエンスコーパス: adverse cardiovascular event

1 (procedural complications, in-hospital major adverse cardiovascular event).

2 ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events).

3 detected T2DM patients with a previous major adverse cardiovascular event.

4 No patient suffered from in-hospital major adverse cardiovascular event.

5 ment were correlated with lower 30-day major adverse cardiovascular event.

6 ocardial ischemia and also be a predictor of adverse cardiovascular events.

7 enced an end point; 29 died and 33 had major adverse cardiovascular events.

8 and a secondary combined end point for major adverse cardiovascular events.

9 with clopidogrel for the prevention of major adverse cardiovascular events.

10 , transient ischemic attack (TIA), and major adverse cardiovascular events.

11 essure lowering, and a reduced risk of major adverse cardiovascular events.

12 ndpoints included 30-day mortality and major adverse cardiovascular events.

13 e an independent predictor of 12-month major adverse cardiovascular events.

14 Secondary outcomes included major adverse cardiovascular events.

15 d serious infections, malignancies, or major adverse cardiovascular events.

16 red EPD use in all-cause mortality and major adverse cardiovascular events.

17 f sex, CFR, and angiographic CAD severity on adverse cardiovascular events.

18 t PCI were primary outcomes comprising major adverse cardiovascular events.

19 heart rate has been unequivocally linked to adverse cardiovascular events.

20 onfatal), all-cause death, and other serious adverse cardiovascular events.

21 magnetic resonance imaging (MRI) to predict adverse cardiovascular events.

22 d is associated with increased mortality and adverse cardiovascular events.

23 The primary outcome was major adverse cardiovascular events.

24 etabolic syndrome (MetS) doubles the risk of adverse cardiovascular events.

25 t difference in a composite outcome of major adverse cardiovascular events.

26 Results were similar for major adverse cardiovascular events.

27 indicated in patients at low risk for major adverse cardiovascular events.

28 noninferior to placebo with respect to major adverse cardiovascular events.

29 d not significantly reduce the risk of major adverse cardiovascular events.

30 and unlikely to experience longer-term major adverse cardiovascular events.

31 good calibration for predicting 5-year major adverse cardiovascular events.

32 h leuprolide, with a 54% lower risk of major adverse cardiovascular events.

33 eart failure (HF) are at high risk for major adverse cardiovascular events.

34 ortality (HR 0.53 [95% CI 0.40-0.71]), major adverse cardiovascular events (0.78 [0.69-0.87]), and ho

35 2016 were 0.73 (95% CI, 0.62-0.84) for major adverse cardiovascular events, 0.92 (95% CI, 0.85-1.00)

36 -up of 31+/-9 months, the incidence of major adverse cardiovascular events (12.54 % versus 11.25%; od

37 ears; HR, 0.57; 95% CI, 0.50-0.65) and major adverse cardiovascular events (2.31 versus 3.45 events p

38 tic cardiovascular disease), with 3342 major adverse cardiovascular events, 2028 cardiovascular death

39 d was associated with a higher risk of major adverse cardiovascular event (23.2% versus 13.4%; OR, 3.

40 gliflozin reduced the risks of 3-point major adverse cardiovascular events (3-point MACE), cardiovasc

41 Study outcomes included in-hospital major adverse cardiovascular events, 30-day mortality, and 1-y

42 isease have lower rates of in-hospital major adverse cardiovascular events, 30-day mortality, and 1-y

43 s (85% versus 94%; P<0.001) and higher major adverse cardiovascular events (4.3% versus 1.1%; P<0.001

44 e no significant differences in 30-day major adverse cardiovascular events (4.8% versus 5.4%, P=0.73;

45 risk of death (40.9% versus 54.5%) and major adverse cardiovascular events (47.6% versus 59.5%), but

46 o with respect to the primary outcome, major adverse cardiovascular events (a composite of death from

47 udied on 30-day mortality, in-hospital major adverse cardiovascular events (a composite of in-hospita

48 therapy was associated with increased major adverse cardiovascular event (adjusted hazard ratio, 1.4

49 increased survival and greater freedom from adverse cardiovascular events after complete revasculari

50 al arterial disease (PAD) have high rates of adverse cardiovascular events after percutaneous coronar

51 o gap in pharmacy supply >30 days) and major adverse cardiovascular events (all-cause death, myocardi

52 events, defined as the combination of major adverse cardiovascular events (all-cause mortality, myoc

53 d point, the risk for the composite of major adverse cardiovascular events among the groups was simil

54 ed with 60% increased hazard ratio for major adverse cardiovascular events and 30% increased hazard o

55 own to be an independent predictor for major adverse cardiovascular events and adverse left ventricul

56 These individuals have a high prevalence of adverse cardiovascular events and are defined as having

57 parathyroid hormone levels raise the risk of adverse cardiovascular events and atraumatic bone fractu

58 uently reported a reduction in 3-point major adverse cardiovascular events and HF hospitalization ris

59 hospitalization for heart failure, and major adverse cardiovascular events and higher risk of below-k

60 ntricular (LV) remodeling is associated with adverse cardiovascular events and is frequently observed

61 examined the effects of rivaroxaban on major adverse cardiovascular events and major bleeding in pati

62 with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increase

63 rapy was associated with lower risk of major adverse cardiovascular events and nearly 1 month more ho

64 yceride levels are associated with a risk of adverse cardiovascular events and pancreatitis.

65 heart disease (ACHD), the long-term risks of adverse cardiovascular events and relationship with conv

66 tion because they decrease the risk of major adverse cardiovascular events and slow progression of di

67 PHOENIX, cangrelor reduced the odds of major adverse cardiovascular events and stent thrombosis in wo

68 on the potential for decreasing the risk of adverse cardiovascular events and the possibility of pre

69 let therapy and their association with major adverse cardiovascular events and TIMI bleeding events w

70 dels to predict the risk of death or a major adverse cardiovascular event, and their differences (ie,

71 sclerotic plaques are destabilizing, predict adverse cardiovascular events, and are associated with i

72 t study to analyze long-term survival, major adverse cardiovascular events, and factors associated wi

73 subsequent 5-year all-cause mortality, major adverse cardiovascular events, and initiation of kidney

74 ce of VHD increased the risk of death, major adverse cardiovascular events, and major bleeding but di

75 ation, and the composite end points of major adverse cardiovascular events, and net adverse clinical

76 on, cognition, serious adverse events, major adverse cardiovascular events, and other adverse events.

77 ; and 3) reported all-cause mortality, major adverse cardiovascular events, and other outcomes of int

78 or arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous th

79 studies indicate that these daily rhythms in adverse cardiovascular events are at least partially und

80 d, the mechanisms through which NSAIDs cause adverse cardiovascular events are not entirely understoo

81 al injury have a similar crude rate of major adverse cardiovascular events as those with type 1 myoca

82 We aimed to quantify the risk of adverse cardiovascular events associated with lower-comp

83 of subsequent all-cause mortality and major adverse cardiovascular events at 1 year after discharge,

84 similar by sex, the cumulative rate of major adverse cardiovascular events at 1 year was higher in yo

85 for cessation, and associated risk of major adverse cardiovascular events at 1 year.

86 The rate of major adverse cardiovascular events at 5 years was 31.0% in th

87 ciated with a significant reduction in major adverse cardiovascular events at 5 years, with the large

88 associated with a similar incidence of major adverse cardiovascular event but a lower incidence of ta

89 ents with PAD are at risk for not only major adverse cardiovascular events but also major adverse lim

90 higher absolute risks of mortality and major adverse cardiovascular events, but also with a lower abs

91 e, acarbose did not reduce the risk of major adverse cardiovascular events, but did reduce the incide

92 dicated in patients with a low risk of major adverse cardiovascular events, but may be useful in pati

93 inhibitors demonstrated reductions in major adverse cardiovascular events, but not death.

94 tor, plus acetylsalicylic acid reduced major adverse cardiovascular event by 24%, major adverse limb

95 SGLT2i reduced major adverse cardiovascular events by 11% (HR 0.89 [95% CI 0.

96 ary heart disease by 27% (P=0.002) and major adverse cardiovascular events by 25% (P=0.004) consisten

97 ary heart disease by 27% (P=0.033) and major adverse cardiovascular events by 25% (P=0.037) during th

98 0.73 [0.69-0.76] for CABG) and 5-year major adverse cardiovascular events (C-index=0.65 [0.61-0.69]

99 r predicting 10-year deaths and 5-year major adverse cardiovascular events can help to identify indiv

100 imary safety endpoint was freedom from major adverse cardiovascular events (cardiac death, myocardial

101 Key outcomes were major adverse cardiovascular events (cardiovascular death, non

102 tigated were cardiovascular mortality, major adverse cardiovascular events (cardiovascular mortality,

103 the effects of canakinumab on rates of major adverse cardiovascular events, cardiovascular mortality,

104 s in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality,

105 ntagonists further reduces the risk of major adverse cardiovascular events compared with acetylsalicy

106 irin had similar relative reduction in major adverse cardiovascular events compared with aspirin in p

107 ban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone

108 f-label use associated with increased 30-day adverse cardiovascular events compared with the lowest t

109 analysis was the first occurrence of a major adverse cardiovascular event (death from cardiovascular

110 In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart

111 Study end points consisted of major adverse cardiovascular events (death, myocardial infarct

112 Secondary outcomes included major adverse cardiovascular events (death, myocardial infarct

113 omes and Measures: Death, readmission, major adverse cardiovascular events (death, recurrent MI, stro

114 r serious complications, lower risk of major adverse cardiovascular events, death, new MI, and new on

115 etween management practices and 30-day major adverse cardiovascular events defined as all-cause morta

116 The primary outcome was major adverse cardiovascular events defined as the composite o

117 a model to predict the 5-year risk of major adverse cardiovascular events (defined as a composite of

118 spitalization for heart failure event, major adverse cardiovascular events (defined as all-cause mort

119 ion between medical therapy status and major adverse cardiovascular events, defined as all-cause mort

120 edications on the primary end point of major adverse cardiovascular events, defined as cardiovascular

121 m any cause and a composite outcome of major adverse cardiovascular events, defined as death from any

122 The 30-day coprimary outcomes were major adverse cardiovascular events, defined as death, myocard

123 Although in-hospital mortality and major adverse cardiovascular events did not differ by race/eth

124 rdiovascular disease, the incidence of major adverse cardiovascular events did not differ significant

125 on results in significant reduction in major adverse cardiovascular events driven largely by reductio

126 eous coronary intervention is a predictor of adverse cardiovascular events during follow-up.

127 d higher risk (>=1%) for perioperative major adverse cardiovascular events during the surgical hospit

128 Secondary outcomes included major adverse cardiovascular events (eg, nonfatal myocardial i

129 as associated with a lower rate of the major adverse cardiovascular event end point (HR, 0.68; 95% CI

130 ctivity resulting in increased risk of major adverse cardiovascular events, especially after percutan

131 l components of the composite outcome, major adverse cardiovascular events, fatal CVD, myocardial inf

132 rent care was projected to avert 40-54 major adverse cardiovascular events for every 1000 patients tr

133 prasugrel and clopidogrel had similar major adverse cardiovascular events (hazard ratio [HR], 0.98;

134 ry endpoint was all-cause mortality or major adverse cardiovascular event-hospitalization for nonfata

135 to 2.97), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vas

136 confidence interval [CI], 2.14-2.22), major adverse cardiovascular events (HR, 1.37; 95% CI, 1.34-1.

137 interval [CI]:1.26 to 1.56; p <0.001), major adverse cardiovascular events (HR: 1.29; 95% CI: 1.16 to

138 was a composite of first occurrence of major adverse cardiovascular events (ie, cardiovascular death,

139 The primary trial outcome (major adverse cardiovascular events, ie, coronary heart diseas

140 inumab significantly reduces the first major adverse cardiovascular event in patients with prior myoc

141 as associated with all-cause mortality/major adverse cardiovascular event in univariate (hazard ratio

142 ed to identify individuals at risk for major adverse cardiovascular events in a community-based cohor

143 erioperative myocardial infarction and major adverse cardiovascular events in adults aged 75 years or

144 ervention did not significantly reduce major adverse cardiovascular events in any voucher use likelih

145 rtery calcium (CAC) to predict risk of major adverse cardiovascular events in asymptomatic patients i

146 ega-3 fatty acid formulation to reduce major adverse cardiovascular events in high-risk patients.

147 tatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Re

148 were associated with increased risk of major adverse cardiovascular events in individuals <55 years o

149 Considering the high risk for major adverse cardiovascular events in patients receiving hemo

150 tudied associations between LGE presence and adverse cardiovascular events in patients with dilated c

151 ric bypass and sleeve gastrectomy) and major adverse cardiovascular events in patients with previous

152 orter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 di

153 al registries have shown reductions in major adverse cardiovascular events in psoriasis patients and

154 mia is supported by a 25% reduction in major adverse cardiovascular events in REDUCE-IT (Reduction of

155 There were 2 adverse cardiovascular events in the metoprolol group an

156 cizumab had no benefit with respect to major adverse cardiovascular events in the trial involving low

157 isease was an independent predictor of major adverse cardiovascular events in those with type 2 myoca

158 d a 29% age-adjusted incidence rate of major adverse cardiovascular events, in contrast to 13% in ind

159 ences in 30-day mortality, in-hospital major adverse cardiovascular events, in-hospital stroke, and i

160 t, with a primary endpoint of a composite of adverse cardiovascular events including myocardial infar

161 Two nonmelanoma skin cancers and two major adverse cardiovascular events, including a fatal stroke,

162 Longer-term (up to 4 years) major adverse cardiovascular events, including all-cause death

163 .0 years) for a composite end point of major adverse cardiovascular events, including cardiovascular

164 dence-based medication persistence and major adverse cardiovascular events is unknown.

165 100 mg once daily reduced the primary major adverse cardiovascular event (MACE) outcome of cardiovas

166 ti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some

167 h multivessel disease results in lower major adverse cardiovascular events (MACE) (all-cause death, M

168 All-cause mortality, major adverse cardiovascular events (MACE) (cardiovascular dea

169 to examine the association of sex with major adverse cardiovascular events (MACE) (cardiovascular dea

170 The primary efficacy endpoint was major adverse cardiovascular events (MACE) (cardiovascular dea

171 outcomes were: 1) first occurrence of major adverse cardiovascular events (MACE) (composite of all-c

172 Occurrences of major adverse cardiovascular events (MACE) (defined as CV deat

173 n LA function assessed with MRI-FT and major adverse cardiovascular events (MACE) after AMI.

174 VUS) guidance has been shown to reduce major adverse cardiovascular events (MACE) after PCI, principa

175 The majority of stent-related major adverse cardiovascular events (MACE) after percutaneous

176 n type 9), was associated with reduced major adverse cardiovascular events (MACE) and death in the OD

177 re (BP) control (<120 mm Hg) had fewer major adverse cardiovascular events (MACE) and deaths but high

178 We performed multivariable model for major adverse cardiovascular events (MACE) and determined the

179 apy was associated with a reduction in major adverse cardiovascular events (MACE) and mortality in th

180 r long-term (median 98 months) risk of major adverse cardiovascular events (MACE) and myocardial infa

181 We prospectively studied major adverse cardiovascular events (MACE) at 2 years in 607 p

182 nalyzed for association with death and major adverse cardiovascular events (MACE) at follow-up.

183 r has been shown to reduce the risk of major adverse cardiovascular events (MACE) compared with aspir

184 ry disease (PAD) have a higher risk of major adverse cardiovascular events (MACE) compared with those

185 The primary composite endpoint of major adverse cardiovascular events (MACE) comprised coronary

186 ty lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE) has been observed i

187 chological stress is a risk factor for major adverse cardiovascular events (MACE) in individuals with

188 guideline-recommended therapies reduce major adverse cardiovascular events (MACE) in patients after m

189 re shown to be efficacious in reducing major adverse cardiovascular events (MACE) in patients with CK

190 porter-2 inhibitors reduce the risk of major adverse cardiovascular events (MACE) in patients with ty

191 ular disease (CVD) outcomes as well as major adverse cardiovascular events (MACE) in the Diabetes Con

192 BC) count is associated with increased major adverse cardiovascular events (MACE) in the setting of a

193 d for up to 3 years until at least 122 major adverse cardiovascular events (MACE) occurred.

194 Major adverse cardiovascular events (MACE) were defined as the

195 Predefined end points were major adverse cardiovascular events (MACE) within 12 months.

196 The primary end point was 2-year major adverse cardiovascular events (MACE), a composite of car

197 e associated with a lower incidence of major adverse cardiovascular events (MACE), all-cause mortalit

198 ial effects of their unbalanced use on major adverse cardiovascular events (MACE), defined as cardiov

199 The primary outcome was the report of major adverse cardiovascular events (MACE), defined as inciden

200 e risk of both all-cause mortality and major adverse cardiovascular events (MACE), defined as myocard

201 MR were followed for the occurrence of major adverse cardiovascular events (MACE), defined by cardiov

202 s of stress MBF and MPR with death and major adverse cardiovascular events (MACE), including myocardi

203 Major adverse cardiovascular events (MACE), which included dea

204 r activity [AmygA]) and higher risk of major adverse cardiovascular events (MACE).

205 n(a) and LDL-C independently predicted major adverse cardiovascular events (MACE).

206 n-hospital safety outcome of death and major adverse cardiovascular events (MACE).

207 ciation of a family history of AF with major adverse cardiovascular events (MACE).

208 nary imaging actually result in future major adverse cardiovascular events (MACE).

209 ht loss required to see a reduction in major adverse cardiovascular events (MACE).

210 nuation (Hounsfield units) may predict major adverse cardiovascular events (MACE).

211 owed for incident type 1 and T2MI, and major adverse cardiovascular events (MACE, a composite of all-

212 y associated with a lower incidence of major adverse cardiovascular events (MACE, adjusted HR 0.80, 9

213 Lifetime major adverse cardiovascular events (MACE: cardiovascular deat

214 Rates of 5-year major adverse cardiovascular events (MACE; a composite of card

215 le placebo-controlled trials reporting major adverse cardiovascular events (MACE; ie, cardiovascular

216 infarction and target vessel failure (major adverse cardiovascular events [MACE]).

217 Cardiovascular (major adverse cardiovascular events [MACE], cardiovascular mor

218 ry atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death.

219 ice systolic blood pressure (SBP) with major adverse cardiovascular events (MACEs) and major adverse

220 aseline lipid profile and searched for major adverse cardiovascular events (MACEs) in the high-risk p

221 Major adverse cardiovascular events (MACEs) were analyzed.

222 The study endpoints included composite major adverse cardiovascular events (MACEs), all-cause mortali

223 points included positive angiography, major adverse cardiovascular events (MACEs), and procedural co

224 hip of HTN to the development of other major adverse cardiovascular events (MACEs), including arrhyth

225 he ability of CMR and SPECT to predict major adverse cardiovascular events (MACEs).

226 acy outcomes included 1-year composite major adverse cardiovascular events, moderate to severe bleedi

227 ess than 2 mg/L had a 25% reduction in major adverse cardiovascular events (multivariable adjusted ha

228 re developed for secondary outcomes of major adverse cardiovascular events (myocardial infarction, ca

229 mortality and the secondary outcome of major adverse cardiovascular events (myocardial infarction, he

230 e end point of all-cause mortality and major adverse cardiovascular events (myocardial infarction, st

231 diovascular disease (CVD) and incident major adverse cardiovascular events (myocardial infarction, st

232 Efficacy outcomes included major adverse cardiovascular events (myocardial infarction, st

233 sis is to compare all-cause mortality, major adverse cardiovascular events, myocardial infarction (MI

234 ary outcomes were all-cause mortality, major adverse cardiovascular events, myocardial infarction, he

235 n Index (maxLCBI(4mm)) and non-culprit major adverse cardiovascular events (NC-MACE).

236 potential benefit of CSL112 to reduce major adverse cardiovascular events needs to be assessed in an

237 ne dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 pat

238 Major adverse cardiovascular events occurred in 14.4% of place

239 In the VHR category, major adverse cardiovascular events occurred in 20.4% with mul

240 and 89%, respectively, and in-hospital major adverse cardiovascular events occurred in 31 patients (2

241 Major adverse cardiovascular events occurred in 61 of 1591 pat

242 No major adverse cardiovascular events occurred in either group.

243 ansfusion (odds ratio, 0.74; P=0.009), major adverse cardiovascular events (odds ratio, 0.64; P=0.003

244 1.59-2.03], P<0.001), and in-hospital major adverse cardiovascular events (odds ratio, 1.8 [95% CI,

245 s powered to assess noninferiority for major adverse cardiovascular events of the BioFreedom stent co

246 upadacitinib 15 mg), three adjudicated major adverse cardiovascular events (one [<1%] on upadacitinib

247 et adverse clinical events, defined as major adverse cardiovascular events or Bleeding Academic Resea

248 nce interval [CI], 0.55-1.12; P=0.19), major adverse cardiovascular events (OR, 0.73, CI, 0.51-1.05;

249 pressure) and pathophysiology (eg, onset of adverse cardiovascular events) oscillate during the 24-h

250 The primary major adverse cardiovascular events outcome comprised cardiova

251 The primary major adverse cardiovascular events outcome was not statistica

252 The primary composite major adverse cardiovascular events outcome was time to first

253 which all led to a steady increase in major adverse cardiovascular events over time.

254 vided incremental prognostic value for major adverse cardiovascular events prediction versus establis

255 tive risk reduction in the three-point major adverse cardiovascular event primary outcome (cardiovasc

256 , procedure success rate was 61.4% and major adverse cardiovascular event rate was 4.2%.

257 In revascularization patients, the major adverse cardiovascular events rate was not different acr

258 nts, a significant step-up increase in major adverse cardiovascular events rate was observed across t

259 In the gray zone, the major adverse cardiovascular events rate was similar (37 [13.9

260 sociated with significant reduction in major adverse cardiovascular events (rate ratio =0.48; 95% con

261 sociated with lower success and higher major adverse cardiovascular event rates in comparison to ante

262 spite this finding, the observed crude major adverse cardiovascular event rates were similar between

263 Major adverse cardiovascular event rates were stable beyond th

264 low procedural complications, and low major adverse cardiovascular event rates.

265 tension independently influenced the risk of adverse cardiovascular events, regardless of the definit

266 and 29 (25.4%) experienced a recurrent major adverse cardiovascular event: rehospitalizations due to

267 lower-complexity ACHD had a higher burden of adverse cardiovascular events relative to the general po

268 hibitors protected against the risk of major adverse cardiovascular events (relative risk 0.84 [95% C

269 leeding despite case experience, while major adverse cardiovascular events remained relatively unchan

270 essation was associated with increased major adverse cardiovascular event risk.

271 Major adverse cardiovascular events risk was not significantly

272 mpensation as well as ischemic stroke, major adverse cardiovascular events, splanchnic vein thrombosi

273 een increased plasma TMAO concentrations and adverse cardiovascular events, such as myocardial infarc

274 no difference in all-cause mortality, major adverse cardiovascular events, target vessel revasculari

275 ion that MVO may be more predictive of major adverse cardiovascular events than infarct size itself.

276 bstruction (PMO) is more predictive of major adverse cardiovascular events than myocardial infarct (M

277 oup were less physically active and had more adverse cardiovascular events than patients in the contr

278 e moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to pati

279 -0.85] vs 0.55 [0.34-0.90]), while for major adverse cardiovascular events the HR in the group with c

280 as been associated with an increased risk of adverse cardiovascular events, the accurate incidence of

281 nts: varenicline 11.9%, placebo 11.3%; major adverse cardiovascular events: varenicline 4.0%, placebo

282 ong all the patients, the incidence of major adverse cardiovascular events was 2.9% in the relugolix

283 The event rate of major adverse cardiovascular events was 3.6 events per 100 pat

284 ty endpoint of the 30-day freedom from major adverse cardiovascular events was 92.2%; the lower bound

285 The 8-year cumulative probability of major adverse cardiovascular events was lower in patients unde

286 Overall, no risk reduction on major adverse cardiovascular events was observed (HR: 0.91 [95

287 of early indexes of neutrophilia with major adverse cardiovascular events was studied in a cohort of

288 The primary end point, major adverse cardiovascular events, was defined as the compos

289 placebo on coronary heart disease and major adverse cardiovascular events were assessed over the 4.9

290 fects of liraglutide versus placebo on major adverse cardiovascular events were consistent in patient

291 Major adverse cardiovascular events were higher in the standar

292 Longer-term major adverse cardiovascular events were lower in the CAC-abse

293 The rates of in-hospital major adverse cardiovascular events were significantly lower i

294 GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing

295 er women remained at increased risk of major adverse cardiovascular events, whereas all outcome rates

296 , is associated with greatest risk for major adverse cardiovascular events, while prior peripheral re

297 The absolute risk reduction for major adverse cardiovascular events with alirocumab was numeri

298 lled trial demonstrated a reduction in major adverse cardiovascular events with CoQ10 supplementation

299 significant reduction in time to first major adverse cardiovascular event) with the GLP-1R agonists l

300 educe rates of major bleeding at 48 h or net adverse cardiovascular events within 30 days compared wi